Searched for
PATENTED CANCER DRUG PRICES
NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. ...- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- AYUSH sees rise in patents filings showcasing innovation growth; 4,077 applications filed from 2014 to 2026Ayush-related Intellectual Property activity has seen substantial growth, with over 4,000 patent applications from 2014 to 2026. The Minist...
- Sahajanand Medical Technologies IPO Day 2: Check GMP, subscription status and key detailsSahajanand Medical Technologies IPO entered Day 2 on October 16, 2026, with a 12% GMP and 34% subscription on Day 1. The Rs 475.48-crore of...
- Sahajanand Medical Technologies IPO opens for subscription. Check GMP, price band and key detailsSahajanand Medical Technologies IPO opened for subscription on October 15, 2026, aiming to raise Rs 475.48 crore through an entirely offer-...
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- Pope Leo cancer diagnosis: What is lung adenocarcinoma, symptoms, treatments & who are at riskPope Leo has been found to have lung adenocarcinoma, which is among the most common types of lung cancer. He recently had surgery to excise...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
- Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicinesThe Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning wh...
- Apollo, Max Health, other hospital stocks rally up to 5% despite cancer drug price caps. Why Jefferies stays bullishHospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing med...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Govt set to cap trade margins on more cancer drugs before SC hearingThe Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda w...
- Hospital pricing part of wider value chain: Max MDAbhay Soi, chairman of Max Healthcare, commented on scrutiny regarding hospital pricing in India. He stated that hospitals should be evalua...
- Cancer drug costs Rs 2,700, sells for Rs 27,000: SC questions 10x markup at hospitalsThe Supreme Court has questioned steep markups on cancer drugs and asked the Centre to examine a uniform 16% margin on all medicines. The c...
- Kerala HC says exorbitant drug prices can trigger government intervention in patented medicinesThe Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...
- Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in IndiaNovartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, d...
Load More
